PMDA announcement for patients taking Tavneos Capsules 10 mg and their families
「タブネオスカプセル10mgを服用される患者様とご家族の皆様へ」を掲載しました
Published: 2026-05-21 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-08-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2026-05-21, the Pharmaceuticals and Medical Devices Agency (PMDA) announced that it had posted information addressed to patients taking Tavneos Capsules 10 mg and their families. The title does not specify the safety issue or the advice provided.
Business Impact
Patients taking Tavneos Capsules 10 mg and their families may be affected by the posted information, which specifically addresses them.
Recommended Action
Review of the official PMDA posting would help clarify the safety issue and any advice directed to patients and their families.